Abstract | Increased voiding frequency and urgency are among the most prevalent storage lower urinary tract symptoms (LUTS), often diagnosed as part of overactive bladder syndrome (OAB). It has been suggested that these symptoms are caused by excessive sensory activation of the neural micturition circuit. It seems likely that sensory pathway remodelling is also responsible for pain perception upon bladder filling in patients with bladder pain syndrome (BPS). Neurotrophins-including nerve growth factor (NGF), brain-derived nerve factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4)-represent master modulators of neural plasticity, both in peripheral and central nervous systems. Accumulating evidence points towards a role for neurotrophins in the control of neural sensory function during micturition and indicates their involvement in the emergence of OAB-related and BPS-related LUTS. Neurotrophins could potentially be used as urinary biomarkers to improve diagnostic accuracy for OAB and BPS and monitor therapy effectiveness. Proof-of-principle clinical evidence has confirmed that NGF is a potential target for treating human bladder overactivity.
Introduction
Function of the urinary bladder (the storage and voiding of urine) is controlled by highly complex neural circuits involving supraspinal, spinal and peripheral mechanisms. 1 Increased daytime voiding frequency and urgency to void-resulting from excessive sensory activation of the neural micturition circuit-are among the most prevalent storage lower urinary tract symptoms (LUTS) and are often diagnosed as part of overactive bladder syndrome (OAB). 2 Urgency and frequencyrepresenting storage or 'irritative' LUTS (distinguishable from voiding LUTS) 3 -can arise as a consequence of neurological conditions, such as multiple sclerosis or spinal cord injury (SCI). Storage LUTS can also occur as a result of peripheral disorders, such as BPH and bladder pain syndrome/interstitial cystitis (BPS). However, in many cases, the underlying pathology of OAB is poorly defined (referred to as idiopathic OAB).
Frequently, but not always, storage LUTS are associated with detrusor overactivity during the bladderfilling phase (observed upon urodynamic examination). Detrusor overactivity is thought to contribute towards incontinence episodes and, for this reason, early treatments for OAB-for example, antimuscarinic agents and β 3 -adrenergic agonists-were designed to target excessive detrusor contractility. However, the focus has since shifted towards therapies that target neuronal remodelling, which is responsible for OAB-related storage LUTS. 4, 5 Urgency is the defining (and most bothersome) symptom of OAB and the suppression of urgency implies the inhibition of detrusor overactivity in most patients. Thus, interference with neural plasticity could represent an important therapeutic strategy for tackling both storage LUTS and detrusor overactivity in patients with OAB. In addition to urgency and increased frequency, sensory pathway remodelling is probably also responsible for the perception of pain upon bladder filling in patients with BPS. 6, 7 Analogously to OAB-related LUTS, modulators of sensory neural plasticity could also interfere with bladder pain in BPS.
Neurotrophins-including nerve growth factor (NGF), brain-derived nerve factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4)-represent master modulators of neural plasticity, both in peripheral and central nervous systems. In this Review, we discuss the clinical and experimental evidence that supports a role for neurotrophins in the neural control of bladder function and in the emergence of OAB-related and BPSrelated LUTS. We also consider the potential utility of neurotrophins as urinary biomarkers for improving the accuracy of OAB diagnosis and monitoring therapy efficacy, and review proof-of-principle clinical evidence that confirms NGF as a potential target in the treatment of bladder disorders.
indicates functional alterations of bladder afferents. Normal sensation of bladder filling is communicated to the lumbosacral spinal cord by fast-conducting Aδ-myelinated afferent axons, responding to normal bladder distention and contraction. In addition, unmyelinated C fibres mediate responses to noxious stimulisuch as chemical irritation or inflammation-and do not respond to bladder filling under normal conditions (also known as 'silent' C fibres). In humans, the primary cell bodies of Aδ and C fibres are localized in the lower lumbar (T11-L2) and sacral (S2-S4) dorsal root ganglia (DRG) and project to spinal interneurons and tract neurons, relaying sensory information to central micturition control pathways. 1 Although the Aδ fibre endings are located in the vicinity of the smooth muscle layers, many of the unmyelinated C fibres terminate in the urothelial and immediate suburothelial layers (Figure 1) . 8 It has been suggested that urothelial cells form an important part of the bladder 'sensory web' , responding to stretch or chemical stimuli by producing mediators-such as acetylcholine, ATP and, ultimately, neurotrophins-that modulate the function of underlying urothelial or suburothelial afferent fibres. 9, 10 Intensity of afferent firing is primarily determined by the activity of mechanosensitive, acid-sensitive, ligand-gated and voltage-gated ion channels, including transient receptor potential cation channel vanilloid subfamily (TRPV) members 1 (TRPV1) and 4 (TRPV4) and P2X purinoceptor 2 and P2X purinoceptor 3 (P 2 X 3 ) receptors. 5, 11 Opening of the sensory ion channels can be enhanced or suppressed by a wide variety of uro thelial and inflammatory-cell-derived regulators, including neurotrophins.
Increased pain perception upon bladder filling in patients with BPS and the occurrence of urgency in patients with OAB are associated with sensitization of afferents, resulting from long-term changes in the expression and biological properties of the ion channels and receptors that modulate channel function. Remodelling of the central micturition pathways-either primary or secondary to peripheral sensitization-could eventually lead to excessive efferent stimulation of detrusor muscle and, ultimately, to detrusor overactivity ( Figure 2 ). It is important to note that alternative hypotheses have been proposed to explain the emergence of detrusor over activity. These implicate the primary myogenic, rather than neurogenic, alterations or localized exaggerated sensory responses that lead to the propagation of spontaneous myogenic bladder acti vity, without major involvement of central pathways. 4, 12, 13 Neurotrophins and bladder dysfunction Neurotrophins and their receptors All neurotrophins are structurally related peptides generated from homologous genes that encode prepropeptides. These 240-260 amino acid sequences lose their signalling peptide via proteolytic cleavage to produce propeptides, which are then modified to form mature proteins of 118-129 amino acids. Two identical mature peptides combine to form an active neuro trophin Key points ■ Urgency, frequency and bladder pain are all associated with hypersensitization and remodelling of bladder peripheral afferents ■ Exogenous administration of nerve growth factor (NGF) to the bladder or spinal cord induces bladder overactivity in experimental animal models ■ NGF-and possibly brain-derived neurotrophic factor (BDNF)-is produced in the bladder by urothelium and smooth muscle cells upon stretch and inflammation to sensitize underlying bladder afferent C fibres ■ Peripheral or central NGF sequestration reduces bladder overactivity in experimental models of spinal cord injury, bladder inflammation and outlet obstruction; local NGF delivery improves bladder underactivity in experimental diabetic cystopathy ■ NGF and BDNF represent potential disease biomarkers for bladder pain syndrome/interstitial cystitis (BPS/IC) and overactive bladder syndrome; increased urinary excretion correlates with symptom severity and can be modulated by therapy ■ Neurotrophin system intervention using the monoclonal NGF antibody tanezumab has been shown to improve self-reported bladder pain scores and urgency episode frequency in patients with BPS/IC Neurotrophins modulate neuronal plasticity NGF-a principal neurotrophic peptide-is produced by peripheral tissues to ensure their innervation during organ development. Changes in bladder levels of various neurotrophins have been described during prenatal and postnatal development in rodents. [14] [15] [16] [17] In the bladder, the urothelium and densely innervated detrusor smooth muscle are thought to be the major sources of NGF ( Figure 1 ). In culture, NGF controls the survival and outgrowth (axon and dendrite) of sensory neurons from the DRG, as well as the sympathetic neurons of the major pelvic ganglia (MPG; projecting postganglionic efferent axons to the bladder). 18, 19 This essential facet of neurotrophin action has been demonstrated in the bladders of transgenic mice that overexpress NGF in the urothelium, which are characterized by extensive hyperinnervation caused by nerve fibre expansion of sympathetic neurons, unmyelinated C fibres and Aδ-myelinated afferents. 20 The survival-promoting role of neurotrophins is not restricted to neuronal development; these peptides also protect neurons against various types of injury, including hypoxic, excitotoxic and hypoglycaemic damage. Thus, it is not surprising that infiltrating inflammatory cells such as mast cells can produce NGF, which modulates neuronal function under inflammatory conditions. 21, 22 Elevated bladder NGF levels have been reported in animal models of chemical, neurogenic and immunemediated inflammation, [23] [24] [25] suggesting that an increase in NGF release represents a generalized response to bladder inflammation. 26 During the development of adult organisms, neurotrophins switch roles from prosurvival factors to general regulators of differentiaton and functional neuronal phenotype. This neuromodulation is achieved via the regulation of neuronal expression profiles, including those of neuropeptides, neurotransmitters and membrane ion channels. 11, 27 Peripheral sensory neurons are specifically sensitive to the neuromodulatory effects of NGF, as highlighted by the role of this peptide in the regulation of pain perception. 11, 27 In clinical trials of patients with neuropathy and neurodegeneration, NGF has been shown to induce acute . Increased TRPV1 and MSC activity stimulate the release of urothelial mediators, such as ATP, which sensitize the underlying afferents. In addition, NGF activates TrkA receptors expressed on suburothelial afferent C-fibre terminals, directly sensitizing neuronal TRPV1, MSCs and voltage-gated ion channels (shown in orange). The TrkA-NGF complex is internalized (dashed lines) and retrogradely transported to cell bodies in lumbosacral DRG, where de novo transcription of TRPV1, VGCs, MSCs and additional sensory ion channels (including purinergic P 2 X 3 receptor for ATP; shown in green) is initiated. These newly synthesized ion channels are anterogradely transported back to afferent terminals to contribute to peripheral hypersensitivity. Neurotrophin receptors TrkB (shown in red) and p75 NTR (shown in black) are also expressed on both urothelium and afferent terminals, although their role has not yet been defined. Abbreviations: ATP, adenosine triphosphate; BDNF, brain-derived nerve factor; BOO, bladder outlet obstruction; BPS, bladder pain syndrome; DRG, dorsal root ganglia; MSC, mechanosensory channel; NGF, nerve growth factor; OAB, overactive bladder syndrome; P 2 X 3 , P2X purinoceptor 3; TrkA, tropomyosin-related kinase A; TrkB, tropomyosin-related kinase B; TRPV1, transient receptor potential cation channel vanilloid subfamily member 1; VGC, voltage-gated ion channel.
pain and hyperalgesia. 28, 29 Given that altered sensations in the bladder underlie the symptoms of urgency and frequency, it is not surprising that neurotrophins might be involved in the development of OAB and BPS. 30 Although no data have been published on the effects of exogenous neurotrophin administration on human bladder function, experimental evidence clearly shows that NGF modulates micturition pathways when administered to the bladder or spinal cord. Acute intravesical administration of NGF in rats 31, 32 and transgenic urothelium-specific NGF overexpression in mice 20 result in sensitization of bladder afferents, increased frequency of micturition contractions and reduced micturition threshold (as measured by cystometry). Infusion of NGF into the bladder wall increases the expression of excitatory neurotransmitters, such as calcitonin gene-related peptide in the lumbosacral spinal cord (Figure 2 ). 33 This process, which is thought to involve an uptake of peripheral NGF by TrkA and retrograde transport of the NGF-TrkA complex to DRG cell bodies and their spinal projections, induces synaptic plasticity in the spinal cord ( Figure 2 ). Thus, it is not surprising that not only peripheral, but also intrathecal, delivery of NGF to the lumbosacral spinal cord induces bladder overactivity and modulates the activity of several voltage-gated ion channels-for example, tetrodotoxin-resistant sodium channels and transient A-type potassium channels-in rat DRG afferents. 34 It has been shown that bladder overactivity following the systemic injection of NGF is virtually absent in TRPV1-knockout mice. 35 This implies that modulation of TRPV1-an acid-sensitive, heat-sensitive and capsaicin-sensitive cationic channel-represents the primary mechanism of NGF-induced hypersensitization of bladder afferents 36, 37 and modulation of urothelial function ( Figure 1) . 38 Although several other NGF-induced sensitizing mechanisms have been described in nociceptors, their importance for bladder sensory pathways has not yet been characterized in detail (Figure 2 ).
Several populations of mammalian sensory neurons seem to be dependent on members of the neuro trophin family other than NGF, such as BDNF, NT-3 and NT-4. 18, 39, 40 Similarly to NGF, BDNF has been identified in the peripheral tissues of the bladder, including the urothelium and detrusor muscles. 41, 42 NT-3 and NT-4 might also be expressed in the bladder, although their exact role and location are unclear. 43 Upon TrkAmediated stimulation with NGF, several subpopulations of DRG neurons release BDNF (Figure 2) . 44 postsynaptic ionotropic glutamate N-methyl-D-aspartate receptors, which have a key role in central sensitization.
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Thus, it is feasible that central BDNF might be involved in the regulation of micturition pathways. 42 Neurotrophins in bladder pain syndrome Given that NGF acts as a ubiquitous hyperalgesic mediator, it seems intuitive to study the role of neurotrophins in bladder pain syndromes. BPS-previously known as interstitial cystitis-is characterized by chronic pelvic pain or discomfort that is related to the bladder, accompanied by urgency to void, increased voiding frequency and nocturia, usually without detrusor overactivity. 6, 7, 46, 47 It is a relatively prevalent condition and current therapeutic approaches are often inadequate. 48 However, some patients seem to respond to local botulinum neurotoxin A (BoNT/A) administration. 49, 50 Although the exact nature of BPS remains enigmatic, the presence of both hypersensitivity and urgency symptoms indicates that the neural plasticity of bladder sensory afferents is involved in the development of the disease. Hyperinnervation of suburothelial and detrusor nerve fibres can be detected in bladder biopsies taken from patients with BPS, along with inflammatory infiltration (including a prominent presence of mast cells). 51, 52 Structural and functional damage to the urothelium is thought to represent the key step in BPS pathogenesis. 53, 54 Interestingly, sub urothelial hyperinnervation and tissue mast cell infiltrate have also been observed in transgenic mice that exhibit urothelial NGF overexpression. 20 It is unknown whether the urothelium or mast cells are the primary source of NGF upon bladder inflammation (Figure 1 ). Excessive NGF immunoreactivity has also been observed in the uro thelium and suburothelium of biopsies from patients with BPS. 49, 55 In the latter study, elevated bladder NGF mRNA expression was reduced by effective treatment with pain-reducing trigonal injections of BoNT/A. This neurotoxin is thought to modulate bladder sensations via chemical denervation, by interfering with vesicular transport of neuromediators and membrane ion channels in afferent nerve fibres and urothelium. 56 It is possible that BoNT/A also directly affects NGF release. Patients with BPS excrete large amounts of urinary NGF; levels of this neurotrophin correlate with symptom severity (including self-reported pain-severity scores). 57 Excessive urinary NGF is transiently reduced upon BoNT/A treatment, coinciding with symptomatic improvement. 58 Interestingly, urinary concentration of another neurotrophin, BDNF, is also elevated in patients with BPS and is similarly suppressed following BoNT/A treatment. 58 Several neurotrophin-system interventions alleviate cystometric bladder overactivity in experimental rat models of bladder inflammation (induced by administration of cyclophosphamide, which is converted to the bladder irritant acrolein). Effective interventions include intravesical instillation of modified NGF-antisense oligodeoxynucleotide construct 59 or sequestration of NGF protein using a recombinant fusion protein that consists of an extracellular TrkA domain (directly responsible for NGF binding with the receptor) and the Fc portion of IgG. Studies have shown that NGF sequestration is effective, regardless of whether a systemic intravenous or intrathecal administration route is used, suggesting that both peripheral and central modes of action exist. 60, 61 Intravenous injection of recombinant TrkBIg 2 domain-designed to neutralize BDNF, rather than NGF-reduces the frequency of reflex contractions in animals treated with cyclophosphamide. 42 As TrkB-Ig 2 is unlikely to cross the blood-brain barrier, peripheral uptake of BDNF is probably involved in the modulation of micturition pathway plasticity upon cyclophosphamide-induced inflammation.
Based on these interventional experimental data, the monoclonal NGF-neutralizing antibody tanezumab has been subject to clinical evaluation; phase two trials of drug efficacy have provided encouraging results. In a study of 68 patients with BPS, a single intravenous injection of tanezumab (200 μg/kg) improved selfreported pain score and urgency episode frequency within 6 weeks. 62 Tanezumab had no significant effect on micturition frequency or mean voided volume per micturition. Among the associated adverse effects were abnormal peripheral sensation symptoms, such as paraesthesia and hyperaesthesia. 62 Although clinical studies of NGF monoclonal antibody therapy were put on hold following reports of bone necrosis (requiring total joint replacement in some patients with osteoarthritis), 63, 64 proof-of-concept evidence exists regarding the potential efficacy of systemic intervention in the NGF system for treating BPS.
Neurotrophins in OAB

NGF in neurogenic bladder dysfunction
In humans and animals, suprasacral spinal cord lesions eliminate voluntary control of voiding, leading to an areflexic bladder and urinary retention. However, in the long-term, an automatic spinal reflex develops, resembling primitive neonatal automatic micturition control. Emergence of this reflex is associated with profound neuromodulation of afferent bladder pathways, including sensitization of 'silent' C fibres and increased responsiveness to mechanical stimuli. As a result of this neuronal remodelling, neurogenic detrusor overactivity (NDO) can be detected on cystometry, accompanied by storage LUTS such as increased frequency and urgency. Furthermore, inefficient bladder emptying-resulting from simultaneous bladder and external urethral sphincter contractions (bladder-sphincter dyssynergia)-has been associated with bladder hypertrophy. 1, 65 Similar bladder symptoms are observed in patients with primary neurodegenerative disease, such as multiple sclerosis. 66 Neurotrophins, especially NGF, have been implicated in the neuromodulation of micturition pathway plasticity associated with neurogenic bladder overactivity. In patients with NDO, BoNT/A therapy could improve urodynamic parameters and reduce the occurrence of storage LUTS. 67, 68 NGF production is elevated in the bladder of patients with NDO and can be reduced upon therapy with BoNT/A. 69 Urinary NGF excretion is also increased in patients with NDO, and symptomatic improvement following treatment with antimuscarinics or BoNT/A has been associated with reductions in NGF urinary levels. 68 In experimental animal models of SCI, levels of bladder NGF and BDNF are increased; 43, 70 however, the primary stimulus for NGF release remains unknown. Excessive bladder distension caused by bladder-sphincter dyssynergia might be a contributing factor as stretch induces NGF release from bladder smooth muscle cells (BSMCs). 71, 72 Peripheral NGF could directly modulate afferent plasticity, including expression of TRPV1 and P 2 X 3 receptors. 36, 73 Patients with NDO display abnormally high immunoreactivity towards these receptors in the urothelium and suburothelium (Figure 1) . 67 Increased transport of NGF to DRG cell bodies or central NGF production in the injured spinal cord could modulate the micturition pathway at the spinal level; intrathecal delivery of an NGF monoclonal antibody has been shown to diminish bladder contractions, maximal voiding pressure and ameliorated detrusor-sphincter dyssynergia in rats with SCI. 74, 75 A combination of peripheral and central NGF action is probably involved in the emergence of neurogenic bladder overactivity (although interventional experimental evidence exists only for the latter). Roles for the other neurotrophins have not yet been defined.
Bladder-hypertrophy-associated OAB
Neuronal growth in the bladder is inherently associated with bladder hypertrophy. Hypertrophy of the bladder is most frequently the consequence of bladder outlet obstruction (BOO) caused by benign prostatic hyper plasia (BPH). In this clinical setting, hypertrophy is thought to occur as a compensatory response to restrained emptying of the obstructed bladder. Structurally, hypertrophy of BSMCs and excessive extracellular matrix deposition result in increased bladder wall thickness and bladder weight, both of which are related to the severity of obstruction. 76 Patients with BPH often present with storage LUTS (including frequency and urgency), which are diagnosed as part of OAB. Eventually, detrusor overactivity might be evident upon urodynamic examination. Microscopically, hypertrophy of both DRG and MPG neurons is observed in the hypertrophied bladders of rat models of BOO, implying a role for neurotrophic factors in the development of these conditions. 77, 78 Indeed, men with OAB symptoms and BOO caused by BPH display excessive levels of NGF in bladder tissue 77 and increased levels of urinary NGF. 79 Interestingly, NGF elevation in the urine is reduced following successful BPH treatment with an α-blocker or 5α-reductase inhibitor. 79 Several studies have shown no correlation between urinary NGF levels and urodynamic parameters, possibly indicating that the extent of NGF urinary release reflects the severity of OAB-related storage LUTS, rather than detrusor overactivity severity. [79] [80] [81] In experimental animal models, urinary NGF levels have been shown to correlate with tissue NGF protein levels, which are closely related to rates of symptom clearance following bladder obstruction relief. 82 Most importantly, immunization of rats against NGF not only prevents the rise of NGF in obstructed bladders, but also limits neuronal hypertrophy and associated voiding dysfunction, confirming a causal role for NGF in the emergence of OAB symptoms following BOO. 78 Steers et al. 77 originally proposed that NGF in the hypertrophied bladder is primarily produced by stretched BSMCs; 72, 83 however, more recent evidence suggests that the urothelium is also an important source of NGF. Transgenic mice that overexpress NGF in the urothelium display significant bladder enlargement, along with bladder overactivity and both suburothelial and BSMC hyperinnervation. 20 Urothelial mechanosensory function might be markedly altered in patients with BOO-related OAB. 84 Collectively, these findings suggest that NGF is crucial for the development of storage LUTS in hypertrophied bladders. However, no data are available on the role of the other neurotrophins.
NGF in idiopathic OAB
Urgency and frequency are often reported by patients with no apparent underlying pathology. Detrusor instability observed upon urodynamic examination of such patients is described as idiopathic detrusor overactivity. Several hypotheses have been proposed to explain the emergence of idiopathic detrusor overactivity, implicating either neural plasticity (neurogenic activity) or altered smooth muscle contractility (myogenic activity) as the primary underlying cause. According to one unifying theory, local spontaneous myogenic activity is normally generated via sensory activation of the urothelium, interstitial cells or afferent nerves, and exaggeration of these local responses might contribute to the emergence of urgency and detrusor overactivity. 12 Regardless, the presence of storage LUTS and afferent hypersensitization might suggest a role for neurotrophic factors in the development of idiopathic OAB.
Detrusor biopsies from patients with idiopathic detrusor instability have been shown to contain twice as much NGF as controls. 72 There have been several reports of markedly increased urinary NGF release in patients with idiopathic OAB; 81, [85] [86] [87] one report suggested that urinary NGF release is associated with the presence and severity of urgency. 87 In a study of women with OAB (with or without detrusor overactivity), no relationship was established between levels of NGF in superficial biopsies (largely composed of urothelium and suburothelium) and urodynamic parameters, 88 suggesting that the urinary NGF that accumulates in patients with OAB does not originate from the urothelium. Similarly, elevated levels of serum NGF correlate with urinary NGF excretion in patients with OAB, reinforcing the idea that NGF has a systemic origin in bladder overactivity. 89 Nevertheless, urinary NGF is decreased in response to antimuscarinic and BoNT/A therapies, which improve storage LUTS. Upon treatment withdrawal, abnormal NGF excretion is observed once again. 68, 90 The presence of detrusor overactivity has been associated with further NGF urinary increases in some studies, 91 but not others. 81 As a significant proportion of the available data relate to small cohorts, additional studies are required to better define a role for urinary NGF as a biomarker of idiopathic OAB.
Altered NGF balance in diabetic cystopathy
Patients with diabetes mellitus present with a wide variety of LUTS and diabetic bladder dysfunction is one of the most common diabetic complications, reported in about 50-70% of patients. 92, 93 Increased bladder volumes at first sensation to void have been described, as well as reduced detrusor contractility and excessive postvoid residual volumes, which can eventually lead to atonic bladder. These symptoms have been ascribed to altered afferent and efferent neural regulation, resulting from diabetic neuropathy. However, a large proportion of patients demonstrate symptoms of bladder overactivity (rather than underactivity), including urgency, frequency and, ultimately, detrusor overactivity. The pathophysiology involved in this clinical scenario is complex and difficult to understand. A two-step model of diabetic cystopathy progression has been proposed on the basis of experimental animal studies, 94 which suggest that patients initially develop bladder hypertrophy and overactivity (presumably as an adaptation to polyuria-mediated frequent voiding). As these symptoms resemble those observed in bladders with evidence of BOO or SCI, it seems likely that increased production of neurotrophins might be involved in this phase of diabetic bladder dysfunction. In support of this theory, increased NGF levels have been reported in the bladders of rats with early experimental diabetes mellitus. 95 In more advanced diabetic bladder disease (for example, the decompensated phase of experimental diabetic cysto pathy), bladder and DRG levels of NGF drop 96 and animals display increased bladder capacity and decreased peak pressures, resulting from diabetic neuropathy and hyperglycemia-induced alterations in detrusor muscles and the urethra.
Loss of NGF production has been implicated in the development of sensory and sympathetic neuronal degeneration associated with diabetic neuropathy. 97, 98 As such, recombinant NGF has been subject to clinical evaluation for the treatment of patients with diabetic polyneuropathy. 28 Although data regarding bladder function are lacking for these patients, experimental evidence suggests that NGF improves diabetic bladder dysfunction in the decompensated phase. NGF gene therapy by herpes-virus-mediated NGF gene delivery into the bladder results in long-term elevation of NGF bladder levels, preventing excessive increases in bladder cap acity and reducing postvoid residual volume in diabetic rats. 99 These data provide interventional evidence for a causal role of NGF in the development of diabetic cystopathy. Thus, experimental evidence indicates that NGF levels in the bladder fluctuate during the compensatory and decompensated phases of diabetic bladder dysfunction, possibly actively contributing to functional abnormalities. Diabetic cystopathy represents a progressive dis order in which sensory and contractile bladder dysfunction might be dependent on continually unbalanced neurotrophin production.
Urinary neurotrophins as biomarkers
One of the main problems that urologists face when diagnosing OAB is the lack of an objective diagnostic method. OAB diagnosis relies on the identification of urgency; defined as a sudden compelling desire to void, which is difficult to defer. 2, 3 However, urgency can be easily confused with urge (the normal sensation of bladder fullness, with fully maintained control of bladder function). An objective biomarker-preferably one that is noninvasively detectable in urine with a reasonable sensitivity and specificity-might help clinicians to establish the correct diagnosis in uncertain cases. For instance, patients with stress urinary incontinence (SUI) might mistakenly report urgency to void when urine leaks into the proximal urethra. SUI coexists with OAB in a large fraction of elderly patients with mixed urinary incontinence. In these patients, elevated urinary NGF could be used as a marker to identify patients with OABrelated urgency as SUI does not seem to be associated with changes in urinary NGF excretion. 100 Furthermore, NGF can be employed as an OAB biomarker to assess disease progression. Patients with OAB can develop incontinence (OAB wet), which is associated with higher urinary NGF levels than OAB without incontinence (OAB dry). 91 Importantly, NGF could also be used to monitor therapy efficacy, to establish whether (and when) treatment can be interrupted following symptomatic improvement and to indicate whether asymptomatic patients should resume treatment. Urinary NGF decreases (in parallel with symptomatic improvement) following antimuscarinic treatment and detrusor injections of BoNT/A in patients with OAB or BPS. 57, 58, 68, 90 Importantly, decreased urinary NGF was only noted in responders to the symptom-relieving therapy. Despite recent efforts, multiple issues still need to be resolved before NGF can become a widely accepted clinical biomarker for OAB or BPS. Of particular note are diffi culties regarding the relatively low sensitivity and specificity of the marker and the lack of well-defined normal and cut-off values. 101, 102 Additional studies are needed, involving larger patient cohorts.
Significantly less data are available on the urinary excretion of the other neurotrophins. Interestingly, elevated urinary levels of BDNF are suppressed upon symptomatic improvement following BoNT/A injection in patients with BPS. 58 Similarly, a small study of patients with OAB demonstrated that increases in urinary BDNF were significantly diminished following therapeutic intervention, including lifestyle modification and antimuscarinic treatment. 103 Interestingly, BDNF urinary levels strongly correlated with symptom severity in this trial. Another small study reported elevated urinary concentration of NT-3 in patients with BPS, 104 although the relevance of this finding is not yet clear.
Conclusions
The role of NGF as a crucial regulator of bladder sensory function has been now conclusively established. Proof-of-principle clinical evidence involving the NGF-neutralizing monoclonal antibody tanezumab has confirmed that NGF is a viable therapeutic target for the treatment of BPS. 62 Moreover, several other anti-NGF monoclonal antibodies-including fulranumab and REGN475-are under investigation in phase II trials for multiple indications associated with chronic pain. [105] [106] [107] However, given the widespread neuromodulatory role of NGF, there is great concern regarding the associated 'offtarget' adverse effects of anti-NGF antibodies, including paraesthesia and progressive joint degeneration (potentially requiring joint replacement). 64, 108 Although reports of the latter initially led to the suspension of all clinical trials involving anti-NGF treatment, clinical testing has since resumed. 109 It remains unclear whether reported cases of joint degeneration result from direct skeletal effects of NGF or as a consequence of excessive joint overload in the absence of pain (particularly in the case of patients with osteoarthritis). 64 Eventually, alternative systemic administration routes could be developed for NGF neutralization, such as local bladder injections (which have already been successfully employed for administering BoNT/A to patients with OAB and BPS). 110 However, several pharmacokinetic issues will need to be resolved first. Intravesical liposome instillation-which has been tested in 24 patients with BPS to date 111 -might represent another promising approach for the local delivery of NGF-silencing or NGF-sequestering agents to the bladder. Experimental treatments aimed at sequestering NGF or BDNF include recombinant proteins with TrkA or TrkB Ig 2 binding domains, respectively. 42, 61 Low-molecular-weight compounds that prevent specific interactions between NGF or BDNF and their respective receptors have also been investigated. 112, 113 Small compounds that block the tyrosine kinase activity of TrkA receptors might represent another potential treatment approach. 113 At present, the experimental data that are available for non-NGF neurotrophins are insufficient for these to be considered valid therapeutic targets for bladder dysfunction. Nevertheless, it is likely that these peptides-particularly BDNF-also play an important role in the regulation of bladder sensory function. Unlike neurotrophin blockade, NGF administration and activation of TrkA with low-molecular-weight compounds are unlikely clinical tools for treating diabetic areflexic bladder, as a result of potentially serious nociceptive adverse effects. However, organ-specific delivery of NGF might eliminate or reduce systemic toxicity. Additional studies, involving larger cohorts of patients, are needed to define the sensitivity and diagnostic value of urinary NGF and BDNF markers in patients with OAB-related storage LUTS.
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The primary literature was obtained by searching the MEDLINE database for the keyword "urinary bladder" in combination with the following keywords: "neurotrophins", "NGF" and "BDNF". In addition, relevant clinical papers on the general aspects of overactive bladder syndrome, bladder pain syndrome (previously known as interstitial cystitis) and diabetic cystopathy were selected, as well as mechanistic publications on the neuromodulatory effects of neurotrophins. Only English-language, full-text papers were selected, with the exception of several abstracts reporting significant mechanistic or clinical advances. Web resources such as clinicaltrials.gov were also reviewed for information on the clinical development of NGF-based interventions.
